Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis

…, R Ivanov, G Sciascia do Olival, AE Dias, M Magyari… - Neurology, 2021 - AAN Enterprises
Background and Objectives People with multiple sclerosis (MS) are a vulnerable group for
severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive …

Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies

T Spelman, M Magyari, F Piehl, A Svenningsson… - JAMA …, 2021 - jamanetwork.com
Importance Treatment strategies for relapsing-remitting multiple sclerosis (RRMS) vary
markedly between Denmark and Sweden. The difference in the association of these national …

Apparent changes in the epidemiology and severity of multiple sclerosis

N Koch-Henriksen, M Magyari - Nature Reviews Neurology, 2021 - nature.com
Multiple sclerosis (MS) is an immunological disease that causes acute inflammatory lesions
and chronic inflammation in the CNS, leading to tissue damage and disability. As awareness …

Worldwide incidence and prevalence of neuromyelitis optica: a systematic review

V Papp, M Magyari, O Aktas, T Berger, SA Broadley… - Neurology, 2021 - AAN Enterprises
Objective Since the last epidemiologic review of neuromyelitis optica/neuromyelitis optica
spectrum disorder (NMO/NMOSD), 22 additional studies have been conducted. We …

[HTML][HTML] Comorbidity in multiple sclerosis

M Magyari, PS Sorensen - Frontiers in Neurology, 2020 - frontiersin.org
Comorbidities in patients with multiple sclerosis (MS) has become an area of increasing
interest in the recent years. A comorbidity is defined as any additional disease that coexists in …

Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women

…, LC Thygesen, E Stenager, B Laursen, M Magyari - Neurology, 2018 - AAN Enterprises
Objective To describe the pattern of development of incidence of multiple sclerosis (MS)
over 60 years in Denmark with age-period-cohort analyses and seasonality of birth. Methods …

Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study

…, N Koch-Henriksen, DM Hougaard, M Magyari… - Neurology, 2017 - AAN Enterprises
Objective: As previous research has suggested that exposure to vitamin D insufficiency in
utero may have relevance for the risk of multiple sclerosis (MS), we aimed to examine the …

Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study

…, A Weglewski, PS Sorensen, M Magyari - Neurology, 2020 - AAN Enterprises
Objective To determine the effectiveness of high-efficacy disease-modifying therapies (heDMTs)
vs medium-efficacy disease-modifying therapies (meDMT) as the first treatment choice …

The changing course of multiple sclerosis: rising incidence, change in geographic distribution, disease course, and prognosis

M Magyari, PS Sorensen - Current opinion in neurology, 2019 - journals.lww.com
An increased interest in population-based registries and databases will provide more valid
epidemiological measures and observational studies conducted in well-defined study …

Family planning considerations in people with multiple sclerosis

…, M Houtchens, VG Jokubaitis, M Magyari… - The Lancet …, 2023 - thelancet.com
Multiple sclerosis is often diagnosed in patients who are planning on having children. Although
multiple sclerosis does not negatively influence most pregnancy outcomes, less is known …